Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy.

Area of Science:

• Neurodegenerative diseases
• Tauopathies
• Mitochondrial biology

Background:

• Progressive supranuclear palsy (PSP) is a neurodegenerative disease characterized by motor, gaze, and cognitive deficits.
• PSP involves cortical and subcortical structures and is classified as a tauopathy.
• Evidence suggests impaired mitochondrial energy metabolism in PSP.

Purpose of the Study:

• To review the pathophysiological role of mitochondrial dysfunction in PSP.
• To explore mitochondrial dysfunction as a potential therapeutic target for PSP.

Main Methods:

• Review of laboratory and in vivo studies on PSP.
• Analysis of findings related to mitochondrial energy production and tau pathology.
• Examination of therapeutic strategies targeting mitochondrial dysfunction.

Main Results:

• Mitochondrial energy metabolism impairment is implicated in PSP.
• Failure in mitochondrial energy production may precede tau aggregation and neuronal death.
• Phase II studies show positive effects of agents targeting mitochondrial dysfunction.

Conclusions:

• Mitochondrial dysfunction is a key pathophysiological concept in PSP.
• Targeting mitochondrial dysfunction presents a promising therapeutic strategy for PSP.
• Further clinical studies are needed to validate therapeutic effects.